influenza nasal vaccine, FluMist
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC NAME: Influenza vaccine live, Intranasal
BRAND NAME: FluMist
DRUG CLASS AND MECHANISM: FluMist is a nasal vaccine that protects against infection with the influenza virus or the "flu." FluMist contains live influenza virus that has been weakened so that it causes minimal or no symptoms. When FluMist is inhaled, the body responds to the weakened viruses in FluMist by developing antibodies that fight influenza viruses. These antibodies protect against later infections by the naturally-occurring influenza virus. FluMist is effective only against the strains of influenza virus that are included in it, and the strains of virus change from year to year. FluMist has no effect on the flu once infection has begun. FluMist should be given shortly before the flu season begins to allow time for antibodies to be produced and for protection throughout the entire flu season. FluMist does not prevent 2009 H1N1 (swine flu) virus infection. The FDA approved FluMist in June 2003.
GENERIC AVAILABLE: No.
PREPARATIONS: Intranasal Spray: prefilled single use intranasal spray, 0.2 ml
STORAGE: FluMist should be stored refrigerated between 2 C to 8 C (35 F to 46 F).
PRESCRIBED FOR: FluMist is used for preventing influenza virus infections (flu) in individuals 2 to 49 years of age.
DOSING: Children 2 to 8 years of age who have not previously received. FluMist should be given 2 doses of 0.2 ml at least one month apart. Children 2 to 8 years of age, who previously received FluMist and adults 9 to 49 years of age, should be given 1 dose (0.2 ml) each season. FluMist is administered by inhaling through the nose and is not given by injection. standing position.
Since FluMist contains viruses that are likely to cause the flu in the upcoming season, FluMist developed for previous seasons will not be effective and should not be used.
DRUG INTERACTIONS: Children 5 to 17 years of age who are receiving aspirin therapy should not be given FluMist because of the association between aspirin, influenza infection and Reye's syndrome, a serious disease of the liver.
Use of FluMist together with antiviral drugs that are active against the influenza virus has not been evaluated. Since there is a potential for antiviral drugs to reduce the effectiveness of FluMist (by preventing infection with the weakened viruses in FluMist), antiviral drugs should not be administered until 2 weeks after FluMist therapy, and FluMist should not be administered until 48 hours after antiviral therapy is discontinued.
Administering FluMist with inactivated virus vaccines was not evaluated in FluMist clinical trials, and combining FluMist with other intranasal products had not been evaluated. FluMist did not interfere with and was not affected by measles, mumps, rubella, or varicella live vaccines.
PREGNANCY: FluMist should not be given to pregnant women.
NURSING MOTHERS: Use of FluMist during breastfeeding has not been adequately evaluated, and it is not known whether FluMist is excreted in breast milk.
SIDE EFFECTS: The most common side effects of FluMist are cough, runny nose, nasal congestion, sore throat, headache, restlessness, muscle aches, tiredness or weakness and fever. Hypersensitivity reactions also have been reported. FluMist should not be administered to individuals with asthma because it may increase wheezing.
Last Editorial Review: 11/14/2012
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index